The University of Cincinnati's Yasmin Aziz, MD, and Joseph Broderick, MD, coauthored an editorial published on Nov. 7 in the ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali ... the most common form of the disease.

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

One of the men argued in court that he did not know what “consent” meant. Another said he thought Mr. Pelicot, as her husband, could consent on her behalf. One man told the court he has learne ...

To continue this tradition, SABC 1’s Skeem Saam has aired a controversial episode that touches on how quickly and easily the lines of consent can be blurred. This storyline follows the characters of ...

New Developer Platform delivers more flexibility and control to unlock new workflows, applications, and material options. New bulk material pricing brings prices as low as $35 per liter for SLA ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

The main result is that for the most common form of advanced breast cancer, adding ribociclib to letrozole significantly improved progression-free survival (PFS), as compared to adding a placebo.